Conditions: Mantle Cell Lymphoma
Keywords: Non- Hodgkins Lymphoma
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 28
Healthy volunteers: no

Brief summary:
The purpose of this study is to estimate the disease control rate with abemaciclib for relapsed or refractory mantle cell lymphoma.

Detailed description:

Arms:
arm 1: 200 milligram (mg) abemaciclib administered orally every 12 hours on days 1 through 28 of a 28-day cycle

Interventions: intervention 1: Abemaciclib
Intervention descriptions: intervention 1: Administered orally

Protocol document: